Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha-synuclein, or polyglutamine repeats for induction of an immune response thereto

Abstract

The present invention relates to immunogenic but non-depositing-forming polypeptides or peptides homologous to amyloid β, prion, amylin or α-synuclein which can be used alone or conjugated to an immunostimulatory molecule in an immunizing composition for inducing an immune response to amyloid β peptides and amyloid deposits, to prion protein and prion deposits, to amylin and amylin deposits, to α-synuclein and deposits containing α-synuclein, or to polyglutamine repeats and deposits of proteins containing polyglutamine repeats. Described are also antibodies directed against such peptides, their generation, and their use in methods of passive immunization to such peptides and deposits.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]The present application is a divisional of U.S. patent application Ser. No. 10 / 301,488, filed Nov. 21, 2002, which claims priority under 35 U.S.C. 119(e) of U.S. Provisional Application No. 60 / 331,801, filed Nov. 21, 2001, both of which are hereby incorporated by reference in their entirety.GOVERNMENT LICENSE RIGHTS[0002]The experiments performed in this application were supported in part by the National Institutes of Health, Grant Nos. AG08721, AR02594, AG17617, AG20245, AG02594, AG05891, and AG20197. The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of each respective grant listed above.BACKGROUND OF THE INVENTION[0003]1. Field of the Invention[0004]The present invention relates to the field of amyloid β peptides, prion protein, amylin, α-synuclein, and polyglutamine repeats and methods for indu...

AI Technical Summary

Benefits of technology

[0061]The invention also provides a method of treating or preventing amyloid plaque forming diseases or amyloidosis by the use of a synthetic immunogenic but not deposit forming polypeptide or peptide homologous to the protein which forms the amyloid plaque. In one embodiment, the protein is homologous to the full length protein or peptide, in another embodiment, it includes only a portion of the protein or peptide which forms the amyloid plaque. In one embodiment, at least one residue is substituted with a different amino acid so as to decrease fibrillogenicity and in another embodiment it further includes a polylysine or polyaspartate segment (of 4-10) residues at the N-terminal and or the C-terminal.

[0064]A still further aspect of the invention provides for molecules which include the antigen-binding portion of an antibody specific for the immunogenic polypeptide or peptide of the present invention, as well as for the preparation and use of these molecules. Such molecules include, but are not limited to, antibodies such as monoclonal antibodies, antibody fragments, single chain antibodies, and humanized antibodies. Also provided are pharmaceutical compositions containing such molecules or antibodies together with one or more pharmaceutically acceptable carriers, diluents, excipients or auxiliary agents, as well as methods for reducing the formation of fibrils or deposits of amyloid, prion, amylin, α-synuclein, or a protein with polyglutamine repeats, by administering such compositions to a subject, preferably a human subject, in need thereof.

Problems solved by technology

In addition, Aβ fibrils are toxic in neuronal culture (Yankner et al., 1989) and to some extent when injected into animal brains (Sigurdsson et al., 1996 and 1997).

To date there is no cure or effective therapy for reducing a patient=s amyloid burden or preventing amyloid deposition in AD, and even the unequivocal diagnosis of AD can only be made after postmortem examination of brain tissues for the hallmark neurofibrillary tangles (NFT) and neuritic plaques.

However, the most potent compound, poly-(vinylsulfonate), was acutely toxic.

However, IDOX does not bind native amyloid precursor light chains which suggests that the β-pleated sheet backbone alone is not sufficient to form the optimal structure for IDOX binding, and that it is the fibril cross-β-sheet quaternary structure that is required for maximal IDOX binding.

IDOX, however, is also extremely toxic.

Although the results reported by Schenk et al. provides promise for using immunomodulation as a general approach to treat Alzheimer=s disease, immunization with intact amyloid-β according to Schenk et al. presents problems that make it inappropriate for human use.

Hence, using this approach in humans with a human Aβ peptide may well lead to development of an autoimmune disorder or disease that could make matters worse not better.

Therefore, in humans, it is expected that Aβ1-42, which is used for immunization in Schenk et al., can cross the blood brain barrier and co-deposit on any existing amyloid plaques leading to increased toxicity, and may actually promote plaque formation.

Thirdly, Schenk et al. use a toxic adjuvant to induce an immune response.

This illness manifested by hyper-excitability, itching and ataxia, leads to paralysis and death.

Kuru was once the major cause of death among Fore women; however, the disease has virtually disappeared with the end of cannibalistic rituals.

However, despite extensive searches, no nucleic acid associated with prion infection has been detected so far.

However, it was unaffected by nuclease digestion or UV irradiation.

However, a remaining major problem is that even with current techniques, the ratio of PrPSc molecules to infectious units is on the order of 10,000 to one (Horwich and Weismann, 1997).

Hence, with such a ratio it is very difficult to completely rule out that other essential components are not part of the infectious agent or that some covalent or other post-translational modifications do not occur as part of the PrPC to PrPSc conversion.

Currently, no such therapeutic agents exist.

So far only a limited number of approaches have been attempted.

Some of these compounds delay the incubation time of animals infected with PrPSc but all have limitations in terms of toxicity and / or pharmacokinetics.

Subsequent increase in intracellular calcium may lead to cytotoxcity.

This is a symptomatic treatment but does not address the cause of the disease.

Presently, no effective treatments have been developed for HD or the other polyglutamine diseases (Hughes and Olson, 2001).

Images